Recruiting

Oral 18F-FDG

Sponsor:

British Columbia Cancer Agency

Code:

NCT07295171

Conditions

Multiple Cancers

Multiple Indications Cancer

Feasibility Studies

Eligibility Criteria

Sex: All

Age: 19+

Healthy Volunteers: Not accepted

Interventions

Oral FDG scan

Study Details

Brief summary:

Typically, PET scans involve an IV injection of 18F-FDG that helps identify cancer. Patients are scanned 60 minutes after injecting 18F-FDG. This study aims to assess the feasibility of a different method of administration - oral ingestion (rather than IV) of 18F-FDG through delayed imaging to identify the optimal time for scanning after consuming the drug. The study will aim to recruit 15-24 individuals who will receive two PET scans - one using delayed oral 18F-FDG imaging and a second regular 18F-FDG. The analysis will focus on establishing a suitable protocol for this administration route while considering patient preference and image quality.

Conditions

Multiple Cancers

Multiple Indications Cancer

Feasibility Studies

Study ID

NCT07295171

Start date

Feb 18, 2026

Status verified date

Dec, 2025

Completion date

Feb 18, 2027

Anticipated

Primary completion date

Dec 15, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 19+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age ≥19 years
  • Participants who have received a standard of care \[18F\]FDG PET/CT and are willing to undergo a study specific oral \[18F\]FDG PET/CT within 2 weeks.

Exclusion Criteria:

Participant Inclusion Criteria

  • Age ≥19 years
  • Participants who have received a standard of care \[18F\]FDG PET/CT and are willing to undergo a study specific oral \[18F\]FDG PET/CT within 2 weeks.

Participant Exclusion Criteria

  • Pregnant or breast-feeding
  • Medically unstable (e.g., acute illness, unstable vital signs)
  • Urinary incontinence/catheter.
  • Immobile, frail or vulnerable patients who cannot leave the department and would require an uptake room in any case.
  • Patients whose fasting blood sugar at the SOC PET was >11.0 mmol/l
  • Unable to swallow.
  • Patients with nasogastric tubes, percutaneous gastrostomy or other non-anatomical routes for nutrition.
  • Unable to lie flat for 1h (subset of participants - first 5 participants only).
  • Claustrophobia requiring medication.
  • Undergoing active treatment or assessment of an upper digestive tract tumor (stomach/esophagus)
  • Unable to provide written consent
  • Patients receiving biguanide anti-hyperglycemic agents (e.g. Metformin).
  • Insulin dependent diabetics.

Study Design

Enrollment

27 participants

Anticipated

Intervention Model

Sequential

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Oral FDG scan and standard of care FDG scan

Participants will receive their standard of care FDG scan and then an Oral FDG scan within two weeks.

The standard of care FDG scan will involve IV administration of FDG. The Oral FDG scan will involve FDG diluted in 50ml (approx.) of water to be consumed by mouth.

The length of the oral FDG scans and its comparison to the standard FDG scan depends on which step the study is currently on. Please refer to the Study Design for details on the Oral FDG scan.

Interventions

Oral FDG scan

Evaluating the feasibility, scan quality and ease of administration when FDG is consumed orally rather than administered by IV.

Primary outcome measure

  • Number of hours for radiopharmaceutical to be cleared from stomach for optimal imaging [ Time Frame: Periprocedural ]
  • Image quality compared to the standard of care FDG scan [ Time Frame: within 2 weeks of the scan ]
  • To assess participant preference for this method of administering radiopharmaceutical [ Time Frame: periprocedural ]

Central Contacts and Locations

Central contacts

Pavithraa Administrative Research Manager

6048776000pavithraa.ravi@bccancer.bc.ca

Locations

BC Cancer Vancouver

Recruiting

Vancouver, British Columbia, Canada, V5Z 4E6

Contacts

Pavithraa Ravi

pavithraa.ravi@bccancer.bc.ca

Principal Investigator:

Dr. Ian Alberts, MA MBBS MD PhD FEBNM

More Information

Sponsor

British Columbia Cancer Agency

Last update posted

Mar 31, 2026

Last verified

Dec, 2025

Keywords

  • Oral FDG
  • LAFOV
  • Long-axial Field-of-view Scanner
  • Quadra
  • Low-dose Oral Radiopharmaceuticals

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by British Columbia Cancer Agency on 2026-03-31.